Search Page

1

Cite

Share

Biologics in rheumatoid arthritis: where are we going?

Fechtenbaum M, Nam JL, Emery P. Fechtenbaum M, et al. Among authors: nam jl. Br J Hosp Med (Lond). 2014 Aug;75(8):448-9, 451-6. doi: 10.12968/hmed.2014.75.8.448. Br J Hosp Med (Lond). 2014. PMID: 25111096 Review.

Cite

Share

2

Cite

Share

Rheumatoid arthritis management of early disease.

Nam JL. Nam JL. Curr Opin Rheumatol. 2016 May;28(3):267-74. doi: 10.1097/BOR.0000000000000276. Curr Opin Rheumatol. 2016. PMID: 26978129 Review.

Cite

Share

3

Cite

Share

Role of ultrasound imaging in individuals at risk of RA.

Nam JL, D'Agostino MA. Nam JL, et al. Best Pract Res Clin Rheumatol. 2017 Feb;31(1):71-79. doi: 10.1016/j.berh.2017.09.002. Epub 2017 Sep 27. Best Pract Res Clin Rheumatol. 2017. PMID: 29221600 Review.

Cite

Share

4

Cite

Share

Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.

Fitton J, Melville AR, Emery P, Nam JL, Buch MH. Fitton J, et al. Among authors: nam jl. Rheumatology (Oxford). 2021 Sep 1;60(9):4048-4054. doi: 10.1093/rheumatology/keaa858. Rheumatology (Oxford). 2021. PMID: 33331938 Free article.

Cite

Share

5

Cite

Share

Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients.

Taylor JC, Bongartz T, Massey J, Mifsud B, Spiliopoulou A, Scott IC, Wang J, Morgan M, Plant D, Colombo M, Orchard P, Twigg S, McInnes IB, Porter D, Freeston JE, Nam JL, Cordell HJ, Isaacs JD, Strathdee JL, Arnett D, de Hair MJH, Tak PP, Aslibekyan S, van Vollenhoven RF, Padyukov L, Bridges SL, Pitzalis C, Cope AP, Verstappen SMM, Emery P, Barnes MR, Agakov F, McKeigue P, Mushiroda T, Kubo M, Weinshilboum R, Barton A, Morgan AW, Barrett JH; MATURA; and PAMERA; Consortia. Taylor JC, et al. Among authors: nam jl. Pharmacogenomics J. 2018 Jul;18(4):528-538. doi: 10.1038/s41397-018-0025-5. Epub 2018 May 25. Pharmacogenomics J. 2018. PMID: 29795407 Free article. Review.

Cite

Share

6

Cite

Share

Is there a place for initial treatment with biological DMARDs in the early phase of RA?

Nam JL, Emery P. Nam JL, et al. Best Pract Res Clin Rheumatol. 2013 Aug;27(4):537-54. doi: 10.1016/j.berh.2013.09.003. Epub 2013 Oct 4. Best Pract Res Clin Rheumatol. 2013. PMID: 24315053 Review.

Cite

Share

7

Cite

Share

In anti-CCP+ at-risk individuals, radiographic bone erosions are uncommon and are not associated with the development of clinical arthritis.

Di Matteo A, Mankia K, Nam JL, Cipolletta E, Garcia-Montoya L, Duquenne L, Rowbotham E, Emery P. Di Matteo A, et al. Among authors: nam jl. Rheumatology (Oxford). 2021 Jul 1;60(7):3156-3164. doi: 10.1093/rheumatology/keaa761. Rheumatology (Oxford). 2021. PMID: 33415335 Free article.

Cite

Share

8

Cite

Share

Ultrasound subclinical synovitis in anti-CCP+ at-risk individuals with MSK symptoms: an important and predictable stage in the RA continuum.

Di Matteo A, Duquenne L, Cipolletta E, Nam JL, Garcia-Montoya L, Wakefield RJ, Mahler M, Mankia K, Emery P. Di Matteo A, et al. Among authors: nam jl. Rheumatology (Oxford). 2021 Nov 24:keab862. doi: 10.1093/rheumatology/keab862. Online ahead of print. Rheumatology (Oxford). 2021. PMID: 34849610 Free article.

Cite

Share

9

Cite

Share

Individuals at risk of rheumatoid arthritis - The evolving story.

Emery P, Mankia K, Nam JL. Emery P, et al. Among authors: nam jl. Best Pract Res Clin Rheumatol. 2017 Feb;31(1):1-2. doi: 10.1016/j.berh.2017.11.003. Epub 2017 Nov 15. Best Pract Res Clin Rheumatol. 2017. PMID: 29221593 No abstract available.

Cite

Share

10

Cite

Share

A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis.

Villeneuve E, Nam JL, Bell MJ, Deighton CM, Felson DT, Hazes JM, McInnes IB, Silman AJ, Solomon DH, Thompson AE, White PH, Bykerk VP, Emery P. Villeneuve E, et al. Among authors: nam jl. Ann Rheum Dis. 2013 Jan;72(1):13-22. doi: 10.1136/annrheumdis-2011-201063. Epub 2012 Apr 24. Ann Rheum Dis. 2013. PMID: 22532640 Review.

Cite

Share